Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) R&D In Process (2024)

Indivior Pharmaceuticals has reported R&D In Process over the past 1 years, most recently at $1.0 million for Q3 2024.

  • For Q3 2024, R&D In Process changed N/A year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, changed N/A, while the annual FY2024 figure was $1.0 million, 99.38% down from the prior year.
  • R&D In Process for Q3 2024 was $1.0 million at Indivior Pharmaceuticals.
  • Over five years, R&D In Process peaked at $1.0 million in Q3 2024 and troughed at $1.0 million in Q3 2024.